PRECLINICAL REPORTSPredicting the chemosensitivity of ovarian and uterine cancers with the collagen gel droplet culture drug-sensitivity testNagai, Nobutakaa; Minamikawa, Kazuhikob; Mukai, Keijia; Hirata, Eijia; Komatsu, Masaakia; Kobayashi, HisayukibAuthor Information aDepartment of Obstetrics and Gynecology, Hiroshima University Graduate School of Biological Sciences, Hiroshima, Japan bResearch Laboratory Division, Nitta Gelatin, Osaka, Japan Correspondence to N. Nagai, Department of Obstetrics and Gynecology, Hiroshima University Graduate School of Biological Sciences, 1-2-3 Kasumi, Minami-ku, Hiroshima 734-8551, Japan Tel: +81 82 257 5262; fax: +81 82 257 5264; e-mail: [email protected] Received 14 September 2004 Revised form accepted 31 January 2005 Anti-Cancer Drugs: June 2005 - Volume 16 - Issue 5 - p 525-531 Buy Abstract We investigated the utility of the collagen gel droplet culture drug-sensitivity test (CD-DST) for predicting the response of gynecological cancers to chemotherapy. Eighty-three cancer patients were enrolled in this study: 26 ovarian, 29 cervical and 31 endometrial cancers. The CD-DST was performed at various concentrations of drugs. We calculated the T/C ratio, where T is the total volume of the treated culture and C is the total volume of the control culture, and a T/C ratio of 50% or less was defined as sensitive in vitro. The efficacy rate (%) was defined as the number of cultures with a T/C ratio of 50% or less, divided by the total number of evaluable cultures. True-positive cases were defined as clinical responders (complete+partial responses) and true-negative cases were defined as clinical non-responders. The overall tumor evaluation rate was found to be 79.1%. The appropriate drug concentrations were selected as 1.0 μg/ml for cisplatin, 20.0 μg/ml for carboplatin, 1.0 μg/ml for paclitaxel and 0.1 μg/ml for docetaxel by the linear regression equations. The in vitro sensitivity for each drug showed a significant correlation with clinical response rates (r=0.592, p=0021). We therefore conclude that the CD-DST can be used to predict the response to anti-cancer drugs, and may also provide important information by contributing to the development of new chemotherapy regimens. © 2005 Lippincott Williams & Wilkins, Inc.